CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

Autor: Sjoukje J. C. van der Stegen, Tomasz Zabinski, Roseanna Maria Petrovic, Natalie Woodman, Ana C. Parente-Pereira, Michael Sheaff, James Spicer, David M. Davies, Astero Klampatsa, Thivyan Thayaparan, Daniela Achkova, Jennifer R. Cochran, John Maher, Lynsey M. Whilding

Publikováno v: Thayaparan, T, Petrovic, R M G, Achkova, D Y, Zabinski, T S, Davies, D M, Klampatsa, A, Parente Pereira, A C, Whilding, L M, Van Der Stegen, S J C, Woodman, N, Sheaf, M, Cochran, J, Spicer, J F & Maher, J 2017, ' CAR T-cell immunotherapy of MET-expressing malignant mesothelioma ', OncoImmunology, vol. 6, no. 12, e1363137 . https://doi.org/10.1080/2162402X.2017.1363137
OncoImmunology, Vol 6, Iss 12 (2017)

Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors (CAR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c58a7e8d52f1288aa79408ecd60e9e9
https://pubmed.ncbi.nlm.nih.gov/29209570

Targeting of Aberrant alpha v beta 6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

Autor: Ana C. Parente-Pereira, Jose A. Costa-Guerra, Sadaf Ghaem-Maghami, Shobhit Saxena, David M. Davies, Sabari Vallath, Lynsey M. Whilding, John Maher, Y. Vincent Kao, Tomasz Zabinski, Shelia M. Violette, Alex Romain, Hiroaki Itamochi, Roseanna Maria Petrovic, John Marshall

Publikováno v: Whilding, L M, Parente Pereira, A C, Zabinski, T, Davies, D M, Petrovic, R, Kao, V, Saxena, S A, Romain, A, Costa-Guerra, J A, Violette, S, Itamochi, H, Ghaem-Maghami, S, Vallath, S, Marshall, J F & Maher, J 2017, ' Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T-cells ', Molecular Therapy, vol. 25, no. 1, pp. 259-273 . https://doi.org/10.1016/j.ymthe.2016.10.012

Expression of the αvβ6 integrin is upregulated in several solid tumors. By contrast, physiologic expression of this epithelial-specific integrin is restricted to development and epithelial re-modeling. Here, we describe for the first time the devel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbdad42c103c127ac3618e7d1c969fcd
http://hdl.handle.net/10044/1/49361

Abstract B129: Chimeric antigen receptor T-cells targeting the αvβ6 integrin demonstrate potent antitumor activity in multiple solid tumors

Autor: Sadaf Ghaem-Maghami, Shelia M. Violette, Lynsey M. Whilding, Tomasz Zabinski, John Maher, Sabari Vallath, David M. Davies, Roseanna Maria Petrovic, Ana C. Parente-Pereira, John Marshall

Publikováno v: Cancer Immunology Research. 4:B129-B129

Chimeric antigen receptors (CARs) are bespoke fusion molecules that couple the binding of a tumor-associated cell surface target to the delivery of a tailored T-cell activating signal. CAR T-cells targeting CD19 have demonstrated unprecedented effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50c0edfa09cea50e9a304d35b1c54823
https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b129

Abstract 2800: Immunotherapy of malignant pleural mesothelioma using MET specific t – cells

Autor: Sjoukje J. C. van der Stegen, Ana Parente Pereira, John Maher, James Spicer, Roseanna Maria Petrovic, Thivyan Thayaparan

Publikováno v: Cancer Research. 74:2800-2800

Background: Malignant pleural mesothelioma (MPM) is an incurable cancer predominantly induced by asbestos exposure. This aggressive tumor commonly presents at an advanced stage of disease. Although surgery, combination chemotherapy and radiotherapy m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::90c1d1bb5bd067bc07744f04343b381b
https://doi.org/10.1158/1538-7445.am2014-2800